Evidence for higher-order structure formation by the c-myb 18-mer phosphorothioate antisense (codons 2-7) oligodeoxynucleotide: potential relationship to antisense c-myb inhibition

Antisense & Nucleic Acid Drug Development
M VilenchikC A Stein

Abstract

We have demonstrated the formation of higher-order structures (presumably tetraplexes) by an 18-mer phosphorothioate antisense c-myb oligodeoxyribonucleotide that has been shown to have activity in the treatment of leukemia xenograft models. Although not observable by conventionally employed techniques, such as PAGE and dimethyl sulfate (DMS) protection, the formation of such higher-order structures by this oligonucleotide was revealed by several techniques. These included capillary gel electrophoresis (CGE), which demonstrated the presence of molecules with greatly increased retention time compared with the monomer; magnetic circular dichroism spectroscopy, which demonstrated a band at 290 nm, a characteristic of antiparallel tetraplexes; and fluorescence energy transfer measurements. For the last, the 18-mer phosphorothioate oligonucleotide was synthesized with a 5'-fluorescein group. Similar to the molecular beacon model, its fluorescence was quenched when combined in solution with tetraplex-forming oligomers that contained a 3'-Dabcyl moiety. 7-Deazaguanosine inhibits the formation of tetraplexes by eliminated Hoogsteen base pair interactions. The wild-type and 7-deazaguanosine-substituted antisense c-myb oligomers differen...Continue Reading

References

Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M Z RatajczakA M Gewirtz
Aug 11, 1992·Nucleic Acids Research·P BalagurumoorthyV Sasisekharan
Sep 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·R JinK J Breslauer
Jan 14, 1992·Biochemistry·D Sen, W Gilbert
Jan 1, 1991·Annals of the New York Academy of Sciences·A M Gewirtz, B Calabretta
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·G AnfossiB Calabretta
Dec 23, 1988·Journal of Chromatography·A S CohenB L Karger
Apr 1, 1970·Proceedings of the National Academy of Sciences of the United States of America·D Rodbard, A Chrambach
Jan 1, 1980·Methods in Enzymology·A M Maxam, W Gilbert
Jun 1, 1981·Journal of Biochemical and Biophysical Methods·P G RighettiR S Snyder
Feb 25, 1995·Nucleic Acids Research·T C MarshE Henderson
Feb 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·J R WyattD J Ecker
Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·J R PerezR Narayanan
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·N HijiyaA M Gewirtz
Jun 18, 1996·Biochemistry·J R WyattS M Freier
Jan 1, 1997·Methods in Enzymology·M Yang, D P Millar
Feb 3, 1998·Nature Biotechnology·S TyagiF R Kramer
Mar 1, 1996·Nature Biotechnology·S Tyagi, F R Kramer
Jul 1, 1996·Nature Biotechnology·R W WagnerB C Froehler
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·D L SokolA M Gewirtz
Nov 25, 1998·Nucleic Acids Research·L BenimetskayaC A Stein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.